The global drug discovery outsourcing market size is expected to reach around US$6.55 billion by 2030 from US$3.62 billion in 2021 and is expected to grow at an impressive double-digit rate of 6.8% from 2022 to 2030. The technological advancements in the pharmaceutical industry, increasing investments in the research & development, rising prevalence of various chronic diseases, and rising popularity of the biologics are some of the most important drivers of the global drug discovery outsourcing market.
The study includes drivers and restraints of this market. The study provides an analysis of the global drug discovery outsourcing market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1549
Why should you invest in this report?
If you are aiming to enter the global drug discovery outsourcing market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for drug discovery outsourcing are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global drug discovery outsourcing market include:
Albany Molecular Research Inc.
EVOTEC
Laboratory Corporation of America Holdings
GenScript
Pharmaceutical Product Development, LLC.
Charles River
WuXiAppTec
Merck & Co., Inc.
Thermo Fisher Scientific Inc.
Dalton Pharma Services
Oncodesign
Jubilant Biosys
DiscoverX Corporation
QIAGEN
Market Segmentation:
By Workflow
- Target Identification & Screening
- Lead Identification & Candidate Optimization
- Target Validation & Functional Informatics
- Preclinical Development
- Others
By Therapeutic Area
- Oncology
- Cardiovascular
- Gastrointestinal
- Neurology
- Respiratory
- Others
By Drug Type
- Biologics
- Small Molecules
Regional Analysis:
The geographical analysis of the global drug discovery outsourcing market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global drug discovery outsourcing Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global drug discovery outsourcing market in 2030?
- What is the expected CAGR for the drug discovery outsourcing market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global drug discovery outsourcing market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Drug Discovery Outsourcing Market
5.1. COVID-19 Landscape: Drug Discovery Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Drug Discovery Outsourcing Market, By Workflow
8.1. Drug Discovery Outsourcing Market, by Workflow Type, 2022-2030
8.1.1. Target Identification & Screening
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Lead Identification & Candidate Optimization
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Target Validation & Functional Informatics
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Preclinical Development
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Drug Discovery Outsourcing Market, By Therapeutic Area
9.1. Drug Discovery Outsourcing Market, by Therapeutic Area, 2022-2030
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Cardiovascular
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Gastrointestinal
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Neurology
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Respiratory
9.1.5.1. Market Revenue and Forecast (2019-2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Drug Discovery Outsourcing Market, By Drug Type
10.1. Drug Discovery Outsourcing Market, by Drug Type, 2022-2030
10.1.1. Biologics
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Small Molecules
10.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Drug Discovery Outsourcing Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.1.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Drug Type (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Workflow (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Therapeutic Area (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Drug Type (2019-2030)
Chapter 12. Company Profiles
12.1. Albany Molecular Research Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. EVOTEC
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Laboratory Corporation of America Holdings
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. GenScript
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pharmaceutical Product Development, LLC.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Charles River
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. WuXiAppTec
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Merck & Co., Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Thermo Fisher Scientific Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Dalton Pharma Services
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. Oncodesign
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. Jubilant Biosys
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. DiscoverX Corporation
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1549
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments